Sympathetic Activation in Obesity
Primary Purpose
Obesity, Healthy
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PET Scan
Mixed Meal Test
Muscle sympathetic nerve activity (MSNA)
Oral Glucose Tolerance Test
Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)
CT Scan
Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
Sponsored by

About this trial
This is an interventional basic science trial for Obesity
Eligibility Criteria
Inclusion Criteria:In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Age 18-45 years
- In good general health as evidenced by medical history and lean (BMI 18.5-24.9 kg/m2) or non-diabetic obese (BMI 30-50 kg/m2) with a fasting plasma glucose (FPG) <100 mg/dL and a hemoglobin A1c <5.7%.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Hypertension
- Cardiac or pulmonary disease,
- Known history of Type 1 or Type 2 diabetes
- Hepatic disease, swallowing and gastrointestinal disorders
- Current use of anti-obesity medications, supplements and/or anti-hyperglycemic medications
- Neurological injury or illness, and psychiatric medications
- Women who are pregnant or lactating
- Subjects who suffer from claustrophobia
- Subjects who have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this study
- Radiation works or participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits.
- Subjects with history of IV drug use which would prevent venous access for PET tracer injection
- Severe motor problems that prevent the subject from lying still for PET and MR imaging
- Subjects who complain of chronic pain
- Blood donation within 8 weeks of the study
Sites / Locations
- Church Street Research Unit
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Individuals with normal BMI
Individuals with obesity
Arm Description
(BMI 18-25 kg/m2)
(BMI 30-40 kg/m2)
Outcomes
Primary Outcome Measures
[11C]MRB PET imaging of peripheral sympathetic nervous system
20 lean individuals with a BMI of 18-25 and 20 obese individuals with a BMI of 30-40 will undergo a PET/CT scan to determine group differences in sympathetic nervous system (SNS) activity in white adipose tissue (WAT), brown adipose tissue (BAT), and deltoid muscle. SNS activity will be determined by using [11C]MRB a radiotracer for PET imaging.
Microneurography (muscle sympathetic nerve activity (MSNA))
Muscle sympathetic nerve activity will be quantified by identification and measurement of sympathetic bursts in the integrated neurogram and expressed as burst frequency (number of bursts per unit time) to determinate group differences in peroneal MSNA.
Secondary Outcome Measures
Norepinephrine transporter (NET) in the Central Nervous System (CNS)
Regional quantification of [11C]MRB uptake as distribution volume ratio (DVR ) will be used to measure NET in the CNS.
[11C]MRB PET imaging of peripheral sympathetic nervous system after Mixed Meal test
Measurement of peripheral SNS Activity with [11C]MRC for PET/CT before and after a high carbohydrate mixed meal in individuals with normal weight and obesity.
Microneurography (muscle sympathetic nerve activity (MSNA)) after Mixed Meal test
Measurement of MSNS will be obtained before and after a high carbohydrate mixed meal in individuals with normal weight and obesity.
Plasma Glucose
Measurement of plasma glucose levels will be obtained at fasting and during the Mixed Meal Test (MMT). The normal range for glucose levels is 70-100 mg/dL.
Insulin levels
Measurement of plasma insulin levels will be obtained at fasting and during the MMT. Insulin levels in the plasma are higher in individuals with obesity. The normal range for insulin is: < or = 19.6 mcg/dL
C-Peptide
Plasma samples will be drawn at baseline and throughout the MMT for measurement of C-Peptide. The normal range for C-Peptide is 0.80 - 3.85 ng/mL
Plasma Catecholamines (epinephrine and norepinephrine)
Measurement of epinephrine and norepinephrine levels in the plasma at fasting and during the MMT. The normal range for epinephrine is 0 to 140 pg/mL (764.3 pmol/L). The normal range for norepinephrine is 70 to 1700 pg/mL (413.8 to 10048.7 pmol/L).
Plasma Free Fatty Acids (FFA)
Measurement of plasma free fatty acids levels will be obtained at fasting and during the Mixed Meal Test (MMT). FFA levels in the plasma are higher in individuals with obesity than individuals with normal weight.
Thyroid function tests
Plasma samples will be drawn at baseline and throughout the mixed meal test (MMT) for measurement of Thyroid Stimulating Hormone (TSH), free T4 (FT4) and total T3 (TT3). The normal range for TSH is : 0.4-4.5 mlU/L, FT4: 0.8-1.8 ng/dL, TT3: 76 - 181 ng/dL.
Electrocardiogram (EKG)
EKG surface electrodes will be applied to the chest for measurement of heart rate and heart rate variability (QT Interval).
Full Information
NCT ID
NCT04946552
First Posted
June 15, 2021
Last Updated
October 26, 2022
Sponsor
Yale University
Collaborators
National Institutes of Health (NIH)
1. Study Identification
Unique Protocol Identification Number
NCT04946552
Brief Title
Sympathetic Activation in Obesity
Official Title
Sympathetic Activation in Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
November 23, 2021 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
September 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institutes of Health (NIH)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to determine whether sympathetic nervous system (SNS) activity in white adipose tissue (WAT) and brown adipose tissue (BAT), skeletal muscle and brain is altered in individuals with obesity in comparison to individuals with normal weight. Simultaneous multi-organ SNS activation will be obtained with a radiotracer for norepinephrine transporter (NET) for whole-body Positron Emission Tomography (PET) imaging and microneurography (peroneal muscle SNS activity).
The secondary objectives of this study are: 1) to evaluate whether gender differences affect peripheral SNS in healthy normal weight and obese men and women in adipose tissue (WAT and BAT) and muscle (resting/fasting); 2) To investigate the relationship between peripheral and central SNS activity in obesity, by correlating SNS activity in peripheral tissues (WAT, BAT, and muscle) and brain; and 3) To investigate NET CNS and peripheral SNS activity before and after a high carbohydrate mixed meal in lean and obese men and women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Healthy
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Individuals with normal BMI
Arm Type
Active Comparator
Arm Description
(BMI 18-25 kg/m2)
Arm Title
Individuals with obesity
Arm Type
Active Comparator
Arm Description
(BMI 30-40 kg/m2)
Intervention Type
Diagnostic Test
Intervention Name(s)
PET Scan
Intervention Description
Participants will come to the PET Center to undergo the whole body [11C]MRB PET scan. An intravenous bolus dose of MRB (~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
Intervention Type
Dietary Supplement
Intervention Name(s)
Mixed Meal Test
Intervention Description
High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in ~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
Intervention Type
Diagnostic Test
Intervention Name(s)
Muscle sympathetic nerve activity (MSNA)
Intervention Description
Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
Intervention Type
Diagnostic Test
Intervention Name(s)
Oral Glucose Tolerance Test
Intervention Description
Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
Intervention Type
Other
Intervention Name(s)
Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)
Intervention Description
will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
Intervention Type
Diagnostic Test
Intervention Name(s)
CT Scan
Intervention Description
A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV < 1.25 for WAT.
Intervention Type
Other
Intervention Name(s)
Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
Intervention Description
For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
Primary Outcome Measure Information:
Title
[11C]MRB PET imaging of peripheral sympathetic nervous system
Description
20 lean individuals with a BMI of 18-25 and 20 obese individuals with a BMI of 30-40 will undergo a PET/CT scan to determine group differences in sympathetic nervous system (SNS) activity in white adipose tissue (WAT), brown adipose tissue (BAT), and deltoid muscle. SNS activity will be determined by using [11C]MRB a radiotracer for PET imaging.
Time Frame
120 minutes
Title
Microneurography (muscle sympathetic nerve activity (MSNA))
Description
Muscle sympathetic nerve activity will be quantified by identification and measurement of sympathetic bursts in the integrated neurogram and expressed as burst frequency (number of bursts per unit time) to determinate group differences in peroneal MSNA.
Time Frame
30-60 minutes
Secondary Outcome Measure Information:
Title
Norepinephrine transporter (NET) in the Central Nervous System (CNS)
Description
Regional quantification of [11C]MRB uptake as distribution volume ratio (DVR ) will be used to measure NET in the CNS.
Time Frame
120 minutes
Title
[11C]MRB PET imaging of peripheral sympathetic nervous system after Mixed Meal test
Description
Measurement of peripheral SNS Activity with [11C]MRC for PET/CT before and after a high carbohydrate mixed meal in individuals with normal weight and obesity.
Time Frame
120 minutes
Title
Microneurography (muscle sympathetic nerve activity (MSNA)) after Mixed Meal test
Description
Measurement of MSNS will be obtained before and after a high carbohydrate mixed meal in individuals with normal weight and obesity.
Time Frame
2 hours
Title
Plasma Glucose
Description
Measurement of plasma glucose levels will be obtained at fasting and during the Mixed Meal Test (MMT). The normal range for glucose levels is 70-100 mg/dL.
Time Frame
2 hours
Title
Insulin levels
Description
Measurement of plasma insulin levels will be obtained at fasting and during the MMT. Insulin levels in the plasma are higher in individuals with obesity. The normal range for insulin is: < or = 19.6 mcg/dL
Time Frame
2 hours
Title
C-Peptide
Description
Plasma samples will be drawn at baseline and throughout the MMT for measurement of C-Peptide. The normal range for C-Peptide is 0.80 - 3.85 ng/mL
Time Frame
2 hours
Title
Plasma Catecholamines (epinephrine and norepinephrine)
Description
Measurement of epinephrine and norepinephrine levels in the plasma at fasting and during the MMT. The normal range for epinephrine is 0 to 140 pg/mL (764.3 pmol/L). The normal range for norepinephrine is 70 to 1700 pg/mL (413.8 to 10048.7 pmol/L).
Time Frame
2 hours
Title
Plasma Free Fatty Acids (FFA)
Description
Measurement of plasma free fatty acids levels will be obtained at fasting and during the Mixed Meal Test (MMT). FFA levels in the plasma are higher in individuals with obesity than individuals with normal weight.
Time Frame
2 hours
Title
Thyroid function tests
Description
Plasma samples will be drawn at baseline and throughout the mixed meal test (MMT) for measurement of Thyroid Stimulating Hormone (TSH), free T4 (FT4) and total T3 (TT3). The normal range for TSH is : 0.4-4.5 mlU/L, FT4: 0.8-1.8 ng/dL, TT3: 76 - 181 ng/dL.
Time Frame
2 hours
Title
Electrocardiogram (EKG)
Description
EKG surface electrodes will be applied to the chest for measurement of heart rate and heart rate variability (QT Interval).
Time Frame
30-60 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Age 18-45 years
In good general health as evidenced by medical history and lean (BMI 18.5-24.9 kg/m2) or non-diabetic obese (BMI 30-50 kg/m2) with a fasting plasma glucose (FPG) <100 mg/dL and a hemoglobin A1c <5.7%.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Hypertension
Cardiac or pulmonary disease,
Known history of Type 1 or Type 2 diabetes
Hepatic disease, swallowing and gastrointestinal disorders
Current use of anti-obesity medications, supplements and/or anti-hyperglycemic medications
Neurological injury or illness, and psychiatric medications
Women who are pregnant or lactating
Subjects who suffer from claustrophobia
Subjects who have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this study
Radiation works or participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits.
Subjects with history of IV drug use which would prevent venous access for PET tracer injection
Severe motor problems that prevent the subject from lying still for PET and MR imaging
Subjects who complain of chronic pain
Blood donation within 8 weeks of the study
Facility Information:
Facility Name
Church Street Research Unit
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Sympathetic Activation in Obesity
We'll reach out to this number within 24 hrs